A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Pemetrexed (Primary)
- Indications Cancer metastases; CNS cancer; Glioma; Lymphoma; Solid tumours
- Focus Therapeutic Use
- 01 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 01 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 26 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.